Jiangsu Hengrui Pharmaceuticals Proposes Final 2025 Dividend

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) just unveiled an announcement.

Jiangsu Hengrui Pharmaceuticals has proposed a final ordinary cash dividend of RMB 2 per 10 shares for the financial year ended 31 December 2025, with shareholder approval scheduled for 16 April 2026. Details for Hong Kong investors, including payment currency, exchange rate, key dates and withholding tax arrangements, will be announced later, and the company plans to keep the per-share distribution ratio unchanged even if total share capital changes at the record date.

The decision to declare a final dividend underlines the company’s intention to return cash to shareholders and signals confidence in its 2025 financial performance. By committing to a stable payout per share regardless of capital adjustments, Hengrui provides greater visibility on future income for investors, while the pending operational details suggest further clarification will follow as the distribution timetable is finalized.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong that focuses on developing, manufacturing and selling prescription drugs. The group operates in the broader healthcare and life sciences industry, serving domestic and international markets with a portfolio spanning innovative therapies and generic medicines for various clinical areas.

Average Trading Volume: 2,600,925

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$403B

See more data about 1276 stock on TipRanks’ Stock Analysis page.